Advertisement

Fertility, Pregnancy, and Lactation

  • J. van der Giessen
  • C. J. van der WoudeEmail author
Chapter

Abstract

Inflammatory bowel disease (IBD) is a chronic disease of the gastrointestinal tract that affects men and women in their young and reproductive years of life. Anxieties about potentially harmful medication, the effect of pregnancy on disease, the effect of disease on the fetus, and the potential of passing on of disease to offspring result in a relatively high “voluntary” childlessness in young women with IBD. A careful consultation with the parents-to-be on these justified concerns is necessary and involves a proactive approach.

Keywords

Inflammatory bowel disease Fertility Pregnancy Lactation 

References

  1. Adrulonis R, Ferris LK (2012) Treatment of severe psoriasis with ustekinumab during pregnancy. J Drugs Dermatol 11(10):1240–1241Google Scholar
  2. Alsenaid A, Prinz JC (2016) Inadvertant pregnancy during ustekinumab therapy in a patient with plaque psoriasis and impetigo herpetiformis. JEADV 30:488–490PubMedGoogle Scholar
  3. Angelberger S, Reinisch W, Messerschmidt A et al (2011) Long-term follow-up of babies exposed to azathioprine in utero and via breastfeeding. J Crohns Colitis 5(2):95–100PubMedPubMedCentralCrossRefGoogle Scholar
  4. Ban L, Tata LJ, Fiaschi L et al (2014) Limited risks of major congenital anomalies in children of mothers with IBD and effects of medications. Gastroenterology 146(1):76–84PubMedCrossRefGoogle Scholar
  5. Barclay AR, Russell RK, Wilson ML et al (2009) Systematic review: the role of breastfeeding in the development of pediatric inflammatory bowel disease. J Pediatr 155:421–426PubMedCrossRefGoogle Scholar
  6. Beaulieu DB, Ananthakrishnan AN, Issa M et al (2009) Budesonide induction and maintenance therapy for Crohn’s disease during pregnancy. Inflamm Bowel Dis 15(1):25–28PubMedCrossRefGoogle Scholar
  7. Ben-Horin S, Yavzori M, Katz L et al (2010) Adalimumab level in breast milk of a nursing mother. Clin Gastroenterol Hepatol 8(5):475–476PubMedCrossRefGoogle Scholar
  8. Ben-Horin S, Yavzori M, Kopylov U et al (2011) Detection of infliximab in breast milk of nursing mothers with inflammatory bowel disease. J Crohns Colitis 5(6):555–558PubMedCrossRefGoogle Scholar
  9. Bennett RA, Rubin PH, Present DH (1991) Frequency of inflammatory bowel disease in offspring of couples both presenting with inflammatory bowel disease. Gastroenterology 100:1638–1643PubMedCrossRefGoogle Scholar
  10. Bergstrand O, Hellers G (1983) Breast-feeding during infancy in patients who later develop Crohn’s disease. Scand J Gastroenterol 18:903–906PubMedCrossRefGoogle Scholar
  11. Beyer-Berjot L, Maggiori L, Birnbaum D et al (2013) A total laparoscopic approach reduces the infertility rate after ileal pouch-anal anastomosis: a 2-center study. Ann Surg 258(2):275–282PubMedCrossRefGoogle Scholar
  12. de Boer NK, Jarbandhan SV, de Graaf P et al (2006) Azathioprine use during pregnancy: unexpected intrauterine exposure to metabolites. Am J Gastroenterol 101(6):1390–1392PubMedPubMedCentralCrossRefGoogle Scholar
  13. Carmichael SL, Shaw GM, Ma C et al (2007) Maternal corticosteroid use and orofacial clefts. Am J Obstet Gynecol 197(6):585.e1–585.e7 discussion 683–4, e1–7CrossRefGoogle Scholar
  14. Casanova MJ, Chaparro M, Domenech E et al (2013) Safety of thiopurines and anti-TNF-alpha drugs during pregnancy in patients with inflammatory bowel disease. Am J Gastroenterol 108(3):433–440PubMedCrossRefGoogle Scholar
  15. Clowse ME, Wolf DC, Forger F et al (2015) Pregnancy outcomes in subjects exposed to Certolizumab Pegol. J Rheumatol 42(12):2270–2278PubMedCrossRefGoogle Scholar
  16. Coelho J, Beaugerie L, Colombel JF et al (2011) Pregnancy outcome in patients with inflammatory bowel disease treated with thiopurines: cohort from the CESAME study. Gut 60(2):198–203PubMedCrossRefGoogle Scholar
  17. Cornish JA, Tan E, Teare J et al (2007) The effect of restorative proctocolectomy on sexual function, urinary function, fertility, pregnancy and delivery: a systematic review. Dis Colon Rectum 50(8):1128–1138PubMedCrossRefGoogle Scholar
  18. van der Woude CJ, Ardizzone S, Bengtson MB et al (2015) The second European evidenced-based consensus on reproduction and pregnancy in inflammatory bowel disease. J Crohns Colitis 9(2):107–124PubMedPubMedCentralCrossRefGoogle Scholar
  19. Diav-Citrin O, Park YH, Veerasuntharam G et al (1998) The safety of mesalamine in human pregnancy: a prospective controlled cohort study. Gastroenterology 114:23–28PubMedCrossRefGoogle Scholar
  20. Gardiner SJ, Gearry RB, Roberts RL et al (2006) Exposure to thiopurine drugs through breast milk is low based on metabolite concentrations in mother-infant pairs. Br J Clin Pharmacol 62(4):453–456PubMedPubMedCentralCrossRefGoogle Scholar
  21. Gotestam Skorpen C, Hoeltzenbein M, Tincani A et al (2016) The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis 75(5):795–810PubMedCrossRefGoogle Scholar
  22. Habal FM, Hui G, Greenberg GR (1993) Oral 5-aminosalicylic acid for inflammatory bowel disease in pregnancy: safety and clinical course. Gastroenterology 105:1057–1060PubMedCrossRefGoogle Scholar
  23. Hernandez-Diaz S, Su YC, Mitchell AA et al (2013) Medications as a potential source of exposure to phthalates among women of childbearing age. Reprod Toxicol 37:1–5PubMedPubMedCentralCrossRefGoogle Scholar
  24. Homar V, Grosek S, Battelino T (2008) High-dose methylprednisolone in a pregnant woman with Crohn’s disease and adrenal suppression in her newborn. Neonatology 94(4):306–309PubMedCrossRefGoogle Scholar
  25. Hudson M et al (1997) Fertility and pregnancy in inflammatory bowel disease. Int J Gynaecol Obstet 58:229–237PubMedPubMedCentralCrossRefGoogle Scholar
  26. Hviid A, Molgaard-Nielsen D (2011) Corticosteroid use during pregnancy and risk of orofacial clefts. CMAJ 183:796–804PubMedPubMedCentralCrossRefGoogle Scholar
  27. Jurewicz J, Hanke W (2011) Exposure to phthalates: reproductive outcome and children health. A review of epidemiological studies. Int J Occup Med Environ Health 24(2):115–141PubMedCrossRefGoogle Scholar
  28. Kane SV, Acquah LA (2009) Placental transport of immunoglobulins: a clinical review for gastroenterologists who prescribe therapeutic monoclonal antibodies to women during conception and pregnancy. Am J Gastroenterol 104(1):228–233PubMedCrossRefGoogle Scholar
  29. Kanis SL, de Lima-Karagiannis A, de Boer NK, van der Woude CJ (2017) Use of thiopurines during conception and pregnancy not associated with adverse pregnancy outcomes or health of infants at 1 year in a prospective study. Clin Gastroenterol Hepatol 15(8):1232–1241.e1PubMedPubMedCentralCrossRefGoogle Scholar
  30. Kozlowski RD, Steinbrunner JV, Mackenzie AH et al (1990) Outcome of 1st-trimester exposure to low-dose methotrexate in 8 patients with rheumatic disease. Am J Med 88:589–592PubMedCrossRefGoogle Scholar
  31. de Lima A, Zelinkova Z, Mulders AG et al (2016a) Preconception care reduces relapse of inflammatory bowel disease during pregnancy. Clin Gastroenterol Hepatol 14(9):1285–1292PubMedPubMedCentralCrossRefGoogle Scholar
  32. de Lima A, Zelinkova Z, van der Ent C et al (2016b) Tailored anti-TNF therapy during pregnancy in patients with IBD: maternal and fetal safety. Gut 65(8):1261–1268PubMedPubMedCentralCrossRefGoogle Scholar
  33. Lin K, Martin CF, Dassopoulos T et al (2014) Pregnancy outcomes amongst mothers with inflammatory bowel disease exposed to systemic corticosteroids: results of the PIANO registry [abstract]. Gastroenterology 146:S1CrossRefGoogle Scholar
  34. Mahadevan U, Martin CF, Sandler RS et al (2012) PIANO: a 1000 patient prospective registry of pregnancy outcomes in women with ibd exposed to immunomodulators and biologic therapy. Gastroenterology 142:S149CrossRefGoogle Scholar
  35. Mahadevan U, Vermeire S, Lasch K et al (2017) Vedolizumab exposure in pregnancy: outcomes from clinical studies in inflammatory bowel disease. Aliment Pharmacol Ther 45(7):941–950PubMedPubMedCentralCrossRefGoogle Scholar
  36. Mahadevan UMC, Sandler RS (2014) Achievement of developmental milestones among offspring of women with inflammatory bowel disease: the PIANO registry. Gastroenterology 146:S-1CrossRefGoogle Scholar
  37. Martel MJ, Rey E, Beauchesne MF et al (2005) Use of inhaled corticosteroids during pregnancy and risk of pregnancy induced hypertension: nested case-control study. BMJ 330(7485):230PubMedPubMedCentralCrossRefGoogle Scholar
  38. Martin PL, Sachs C, Imai N et al (2010) Development in the cynomolgus macaque following administration of ustekinumab, a human anti-IL-12/23p40 monoclonal antibody, during pregnancy and lactation. Birth Defects Res B Dev Reprod Toxicol 89(5):351–363PubMedPubMedCentralCrossRefGoogle Scholar
  39. Nguyen GC, Seow CH, Maxwell C et al (2016) The Toronto consensus statements for the management of inflammatory bowel disease in pregnancy. Gastroenterology 150(3):734–757PubMedPubMedCentralCrossRefGoogle Scholar
  40. Norgard B, Czeizel AE, Rockenbauer M et al (2001) Population-based case control study of the safety of sulfasalazine use during pregnancy. Aliment Pharmacol Ther 15:483–486PubMedCrossRefGoogle Scholar
  41. Orholm M, Fonager K, Sorensen HT (1999) Risk of ulcerative colitis and Crohn’s disease among offspring of patients with chronic inflammatory bowel disease. Am J Gastroenterol 94:3236–3238PubMedCrossRefGoogle Scholar
  42. Ost L, Wettrell G, Bjorkhem I et al (1985) Prednisolone excretion in human milk. J Pediatr 106:1008–1011PubMedCrossRefGoogle Scholar
  43. Park-Wyllie L, Mazzotta P, Pastuszak A et al (2000) Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology 62:385–392PubMedCrossRefGoogle Scholar
  44. Rahimi R, Nikfar S, Rezaie A et al (2008) Pregnancy outcome in women with inflammatory bowel disease following exposure to 5-aminosalicylic acid drugs: a meta-analysis. Reprod Toxicol 25(2):271–275PubMedCrossRefGoogle Scholar
  45. Rajaratnam SG, Eglinton TW, Hider P et al (2011) Impact of ileal pouch-anal anastomosis on female fertility: meta-analysis and systematic review. Int J Color Dis 26(11):1365–1374CrossRefGoogle Scholar
  46. Rocha K, Piccinin MC, Kalache LF et al (2015) Pregnancy during ustekinumab treatment for severe psoriasis. Dermatology 231(2):103–104PubMedPubMedCentralCrossRefGoogle Scholar
  47. Sheeran C, Nicolopoulos J (2014) Pregnancy outcomes of two patients exposed to ustekinumab in the first trimester. Australas J Dermatol 55(3):235–236PubMedPubMedCentralCrossRefGoogle Scholar
  48. Shim L, Eslick GD, Simring AA et al (2011) The effects of azathioprine on birth outcomes in women with inflammatory bowel disease (IBD). J Crohns Colitis 5(3):234–238PubMedCrossRefGoogle Scholar
  49. Smithells RW, Newman CGH (1992) Recognition of thalidomide defects. J Med Genet 29:716–723PubMedPubMedCentralCrossRefGoogle Scholar
  50. Takeda (2014) Vedolizumab (Entyvio) package insert. Takeda, Cambridge Available from: http://www.general.takedapharm.com Google Scholar
  51. Waljee A, Waljee J, Morris AM et al (2006) Threefold increased risk of infertility: a meta-analysis of infertility after ileal pouch anal anastomosis in ulcerative colitis. Gut 55(11):1575–1580PubMedPubMedCentralCrossRefGoogle Scholar
  52. Zelinkova Z, de Haar C, de Ridder L et al (2011) High intra-uterine exposure to infliximab following maternal anti-TNF treatment during pregnancy. Aliment Pharmacol Ther 33(9):1053–1058PubMedPubMedCentralCrossRefGoogle Scholar
  53. Zelinkova Z, van der Ent C, Bruin KF, van Baalen O, Vermeulen HG, Smalbraak HJ et al (2013) Effects of discontinuing anti-tumor necrosis factor therapy during pregnancy on the course of inflammatory bowel disease and neonatal exposure. Clin Gastroenterol Hepatol 11(3):318–321PubMedCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of Gastroenterology and HepatologyErasmus Medical CenterRotterdamThe Netherlands

Personalised recommendations